Pharma-focused decision analysis software provider Aily Labs added $20.7 million in Series A funds, CEO Bianca Anghelina tells Axios exclusively.
Why it matters: The life science sector's opaque, manual nature results in delays in research, opening a window for startups trying to bring data and transparency to the area.
